Giant cell arteritis in mexican patients

Journal of Clinical Rheumatology

Volumn 18, Issue 1, 2012, Pages 1-7

  Alba, Marco A ^a   Mena Madrazo, Jorge A ^b   Reyes, Edgardo ^c   Flores Suárez, Luis Felipe ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b Department of Geriatrics ^*  (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

amaurosis fugax; cranial ischemia; giant cell arteritis; Mestizos; Mexico

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; HEMOGLOBIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DIABETES MELLITUS; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FACE PAIN; FEMALE; FEVER; FOLLOW UP; GIANT CELL ARTERITIS; HEADACHE; HUMAN; JAW DISEASE; LABORATORY TEST; LEUKOCYTOSIS; MALE; MEDICAL RECORD REVIEW; MEXICO; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; SOUTH AND CENTRAL AMERICA; THROMBOCYTOSIS; TRANSITIONAL BLINDNESS; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; AMAUROSIS FUGAX; ANTIRHEUMATIC AGENTS; BLINDNESS; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; HEADACHE; HUMANS; MALE; METHOTREXATE; MEXICO; MIDDLE AGED; POLYMYALGIA RHEUMATICA; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 84855202287     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823e2e35     Document Type: Article

References (39)

1. Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculidities. Best Pract Res Clin Rheumatol. 2010;24:871-883.
2. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: A 25-year epidemiologic study. Medicine. 2007;86:61-68. (Pubitemid 46668055)
3. Chaudhry IA, Shamsi FA, Elzaridi E, et al. Epidemiology of giant-cell arteritis in an Arab population: A 22-year study. Br J Ophthalmol. 2007;91:715-718. (Pubitemid 46846635)
4. Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government-supported nationwide survey. Arthritis Rheum. 2003;49:594-598. (Pubitemid 36988315)
5. Liu NH, LaBree LD, Feldon SE, et al. The epidemiology of giant cell arteritis: A 12-year retrospective study. Ophthalmology. 2001;108: 1145-1149. (Pubitemid 32500035)
6. Lam BL, Wirthlin RS, Gonzalez A, et al. Giant cell arteritis among Hispanic Americans. Am J Ophthalmol. 2007;143:161-163. (Pubitemid 44917810)
7. Guerra A, Magraner M, Serrano L, et al. Temporal arteritis in Puerto Rico Hispanics. Bol Asoc Med P R. 2006;98:304-311.
8. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-1128. (Pubitemid 20273297)
9. Berger CT, Wolbers M, Meyer P, et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology. 2009;48:258-261.
10. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. Arthritis Rheum. 1998;41:1497-1504. (Pubitemid 28373132)
11. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine. 2009;88:227-235.
12. González-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: Disease patterns of clinical presentation in a series of 240 patients. Medicine. 2005;84:269-276. (Pubitemid 41368480)
13. González-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: Laboratory tests at the time of diagnosis in a series of 240 patients. Medicine. 2005;84:277-290. (Pubitemid 41368481)
14. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26-32. (Pubitemid 28041919)
15. Liozon E, Boutros-Toni F, Ly K, et al. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol. 2003;30:1272-1276. (Pubitemid 36666353)
16. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: A 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978;88:162-167. (Pubitemid 8282146)
17. Sanchez E, Webb RD, Rasmussen A, et al. Genetically determined Amerindian ancestry correlates with increased frequency of risk alleles for systemic lupus erythematosus. Arthritis Rheum. 2010;62: 3722-3729.
18. Gonzalez-Gay MA, Boiardi L, Garcia-Porrua C, et al. Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in Southern Europe. J Rheumatol. 2004;31:520-523. (Pubitemid 38337612)
19. Tal S, Guller V, Gurevich A, et al. Fever of unknown origin in the elderly. J Intern Med. 2002;252:295-304. (Pubitemid 35253697)
20. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318-323.
21. Font C, Cid MC, Coll-Vinent B, et al. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol. 1997;36:251-254.
22. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332-1337. (Pubitemid 38480844)
23. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, et al. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008;38:116-123.
24. Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306-3309. (Pubitemid 44622102)
25. Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine. 2004;83:114-122. (Pubitemid 38524628)
26. González-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine. 2004;83: 342-347. (Pubitemid 39541111)
27. Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology. 2009;48:250-253.
28. Dudenhoefer EJ, Cornblath WT, Schatz MP. Scalp necrosis with giant cell arteritis. Ophthalmology. 1998;105:1875-1878. (Pubitemid 28509727)
29. Chatelain D, Duhaut P, Schmidt J, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis. 2009;68:84-88.
30. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: A prospective study of 174 patients. Am J Med. 2001;111:211-217. (Pubitemid 32786949)
31. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122:502-507.
32. Klein RG, Hunder GG, Stanson AW, et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med. 1975;83:806-812.
33. Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311-317. (Pubitemid 29072849)
34. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum. 2003;48:3522-3531. (Pubitemid 37531919)
35. Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand. 1986;220: 465-469. (Pubitemid 17232395)
36. Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis. 1993;52:847-850. (Pubitemid 24019138)
37. Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheum. 2003;49:703-708. (Pubitemid 37296477)
38. Garcia-Martinez A, Hernandez-Rodriguez J, Grau JM, et al. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51:674-678. (Pubitemid 39056259)
39. Martinez-Lado L, Calvino-Diaz C, Pineiro A, et al. Relapses and recurrences in giant cell arteritis: A population-based study of patients with biopsy-proven disease from Northwestern Spain. Medicine. 2011;90:186-193.